Biotech company Zealand Pharma has recruited all 108 patients required for a phase III study of its drug candidate glepaglutide, which is meant to treat short bowel syndrome, the company announces in a press release.
Zealand Pharma had originally planned to recruit 129 patients for the trial, but the number was then reduced to avoid complications with finding patients due to the Covid-19 pandemic.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.